1207424-55-2

Usage

Uses

Used in Pharmaceutical Industry:
(2-Chloro-6-methyl-pyrimidin-4-yl)-isopropyl-amine is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure and reactivity make it a promising candidate for the synthesis of therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Agrochemical Industry:
In the agrochemical industry, (2-Chloro-6-methyl-pyrimidin-4-yl)-isopropyl-amine is used as a precursor for the synthesis of agrochemicals, such as pesticides and herbicides. Its unique properties and reactivity contribute to the development of more effective and environmentally friendly agrochemical products.
Used in Materials Science:
(2-Chloro-6-methyl-pyrimidin-4-yl)-isopropyl-amine is utilized in materials science for the synthesis of advanced materials with specific properties. Its unique structure and reactivity enable the development of materials with potential applications in various industries, such as electronics, coatings, and polymers.
Used in Organic Synthesis:
As a versatile chemical compound, (2-Chloro-6-methyl-pyrimidin-4-yl)-isopropyl-amine is used in organic synthesis for the preparation of more complex organic compounds. Its unique structure and reactivity make it a valuable building block for the synthesis of various organic molecules with potential applications in different fields.

Upstream product

• 5424-21-5 2,4-dichloro-6-methylpyrimidine 
• 75-31-0 isopropylamine 

Relevant academic research and scientific papers

Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus

The chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus, and it is the causative agent of chikungunya fever (CHIKF). Although it has re-emerged as an epidemic threat, so far there are neither vaccines nor pharmacotherapy available to prevent or treat an infection. Herein, we describe the synthesis and structure-activity relationship studies of a class of novel small molecule inhibitors against CHIKV and the discovery of a new potent inhibitor (compound 6a). The starting point of the optimization process was N-ethyl-6-methyl-2-(4-(4-fluorophenylsulfonyl)piperazine-1-yl)pyrimidine-4-amine (1) with an EC50 of 8.68 μM, a CC50 of 122 μM, and therefore a resulting selectivity index (SI) of 14.2. The optimized compound 6a, however, displays a much lower micromolar antiviral activity (EC50 value of 3.95 μM), considerably better cytotoxic liability (CC50 value of 260 μM) and consequently an improved SI of greater than 61. Therefore, we report the identification of a promising novel compound class that has the potential for further development of antiviral drugs against the CHIKV.

Discovery of a Novel Mycobacterial F-ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines

The F1FO-ATP synthase is required for growth and viability of Mycobacterium tuberculosis and is a validated clinical target. A mycobacterium-specific loop of the enzyme's rotary γ subunit plays a role in the coupling of ATP synthesis within the enzyme complex. We report the discovery of a novel antimycobacterial, termed GaMF1, that targets this γ subunit loop. Biochemical and NMR studies show that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug- as well as bedaquiline-resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity or phenotypic changes in a human embryonic stem cell reporter assay. These results suggest that GaMF1 presents an attractive lead for the discovery of a novel class of anti-tuberculosis F-ATP synthase inhibitors.

ANTIVIRAL COMPOUNDS

The invention is provides novel antiviral compounds, as well as derivatives thereof. The compounds of the invention are preferably formulated as pharmaceuticals. The invention provides the compounds for use in the prevention and treatment of infectious diseases, in particular viral diseases. In some aspects the invention is based on the antiviral activity of the provided compounds against the Chikungunya virus, and hence, their application in the treatment or prevention of any physiological manifestation of such viral infection.

COMPOUNDS FOR TREATING TUBERCULOSIS

The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F1 domain of F-ATP synthase and may be used with bedaquiline or 6-chloro-2-ethyl-N-[[4-[4- [4-(trifluoromethoxy)phenyl]piperidin-1 -yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide (Q203) or a combination thereof.

Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines

Two sets of diaminopyrimidines, totalling 45 compounds, were synthesized and assayed against Plasmodium falciparum. The SAR was relatively shallow, with only the presence of a 2-(pyrrolidin-1-yl)ethyl group at R2 significantly affecting activity. A subsequent series addressed high Log D values by introducing more polar side groups, with the most active compounds possessing diazepine and N-benzyl-4-aminopiperidyl groups at R1/R2. A final series attempted to address high in vitro microsomal clearance by replacing the C6-Me group with CF3, however antiplasmodial activity decreased without any improvement in clearance. The C6-CF3 group decreased hERG inhibition, probably as a result of decreased amine basicity at C2/C4.